Toja-Camba, F.J.; GarcÃa-Quintanilla, L.; RodrÃguez-Martinez, L.; Tomine, J.; Cajade-Pascual, F.; Feitosa, C.; Zarra-Ferro, I.; Barreiro-De-Acosta, M.; González-López, J.; Mondelo-GarcÃa, C.;
et al. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA. Pharmaceutics 2023, 15, 2615.
https://doi.org/10.3390/pharmaceutics15112615
AMA Style
Toja-Camba FJ, GarcÃa-Quintanilla L, RodrÃguez-Martinez L, Tomine J, Cajade-Pascual F, Feitosa C, Zarra-Ferro I, Barreiro-De-Acosta M, González-López J, Mondelo-GarcÃa C,
et al. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA. Pharmaceutics. 2023; 15(11):2615.
https://doi.org/10.3390/pharmaceutics15112615
Chicago/Turabian Style
Toja-Camba, Francisco José, Laura GarcÃa-Quintanilla, Lorena RodrÃguez-Martinez, Julia Tomine, Francisco Cajade-Pascual, Carolina Feitosa, Irene Zarra-Ferro, Manuel Barreiro-De-Acosta, Jaime González-López, Cristina Mondelo-GarcÃa,
and et al. 2023. "Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA" Pharmaceutics 15, no. 11: 2615.
https://doi.org/10.3390/pharmaceutics15112615
APA Style
Toja-Camba, F. J., GarcÃa-Quintanilla, L., RodrÃguez-Martinez, L., Tomine, J., Cajade-Pascual, F., Feitosa, C., Zarra-Ferro, I., Barreiro-De-Acosta, M., González-López, J., Mondelo-GarcÃa, C., & Fernández-Ferreiro, A.
(2023). Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA. Pharmaceutics, 15(11), 2615.
https://doi.org/10.3390/pharmaceutics15112615
